RoosterBio Inc. and GenCure, both regenerative medicine manufacturing technology leaders, have locked into multiple agreements to help companies advance their innovations to clinical testing more rapidly than ever before. Companies across the regenerative medicine industry, ranging from synthetic biology companies that are gene editing therapeutic cells for advanced functionality in vivo, to pioneering medical device companies that bridge the regenerative capabilities of living cells with medical devices, have signed agreements to accelerate their path to clinical testing. These companies are leveraging RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems and rapid product and process development platform, and GenCure’s current Good Manufacturing Practices (cGMP)-compliant hMSC-focused manufacturing facility.

South Texas Blood & Tissue Center (STBTC), a subsidiary of BioBridge Global, will thank blood donors throughout April with $10 Subway gift cards. The community blood center hopes to increase lifesaving blood and platelet donations to help local trauma, surgery and cancer patients like 25-year-old Taylor Castro.

Taylor was diagnosed with acute myeloid leukemia, an aggressive blood cancer, after going to the doctor for an ear infection in October 2018. The diagnosis came just six months after giving birth to her youngest child. Since then, Taylor’s received several rounds of chemotherapy and relies on regular blood and platelet transfusions. She is also searching for a marrow or stem cell match, her only hope for a cure for her leukemia.